These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

75 related articles for article (PubMed ID: 18688215)

  • 1. GSK slashes internal R&D.
    Moran N
    Nat Biotechnol; 2008 Aug; 26(8):840. PubMed ID: 18688215
    [No Abstract]   [Full Text] [Related]  

  • 2. Will R&D make Merck hot again?
    Simons J
    Fortune; 2002 Jul; 146(1):89-90, 92, 94. PubMed ID: 12119729
    [No Abstract]   [Full Text] [Related]  

  • 3. $1 billion R&D spender emerges.
    Ward M
    Nature; 1995 Aug; 376(6542):626. PubMed ID: 7651500
    [No Abstract]   [Full Text] [Related]  

  • 4. Goliath befriends David.
    Clarke T; Pearson H
    Nature; 2001 Nov; 414(6863):482-3. PubMed ID: 11734817
    [No Abstract]   [Full Text] [Related]  

  • 5. Patient heal thyself.
    Benson RS
    Drug Discov Today; 2005 Feb; 10(3):159-61. PubMed ID: 15708524
    [No Abstract]   [Full Text] [Related]  

  • 6. Bigger isn't always better.
    Nature; 2002 Jul; 418(6896):353. PubMed ID: 12140518
    [No Abstract]   [Full Text] [Related]  

  • 7. Singapore R&D and globetrotting.
    Lear MJ; Salmons B; Gunzburg WH; Dangerfield JA
    Biotechnol J; 2009 Feb; 4(2):179-85. PubMed ID: 19156748
    [No Abstract]   [Full Text] [Related]  

  • 8. Payers growing influence on R&D decision making.
    Hughes B
    Nat Rev Drug Discov; 2008 Nov; 7(11):876-8. PubMed ID: 18974741
    [No Abstract]   [Full Text] [Related]  

  • 9. Outsourcing drug work. Pharmaceuticals ship R&D and clinical trials to India.
    Sinha G
    Sci Am; 2004 Aug; 291(2):24-5. PubMed ID: 15298112
    [No Abstract]   [Full Text] [Related]  

  • 10. Portfolio analysis and R&D decision making.
    Evans R; Hinds S; Hammock D
    Nat Rev Drug Discov; 2009 Mar; 8(3):189-90. PubMed ID: 19182818
    [No Abstract]   [Full Text] [Related]  

  • 11. Where does novel antibiotics R&D stand among other pharmaceutical products: an industrial perspective?
    Tillotson GS
    Expert Rev Anti Infect Ther; 2008 Oct; 6(5):551-2. PubMed ID: 18847393
    [No Abstract]   [Full Text] [Related]  

  • 12. The biotechnology industry: What's next?
    Guertin PA
    Biotechnol J; 2009 Aug; 4(8):1124-31. PubMed ID: 19685466
    [No Abstract]   [Full Text] [Related]  

  • 13. Industrial R&D paradigm shift to vaccines.
    Maggon K
    Biotechnol J; 2009 Apr; 4(4):458-61. PubMed ID: 19370719
    [No Abstract]   [Full Text] [Related]  

  • 14. Deal watch: Bristol-Myers Squibb and Exelixis collaborate on kinase inhibitors.
    Nat Rev Drug Discov; 2009 Feb; 8(2):98. PubMed ID: 19180098
    [No Abstract]   [Full Text] [Related]  

  • 15. Pharmaceutical R&D: the road to positive returns.
    David E; Tramontin T; Zemmel R
    Nat Rev Drug Discov; 2009 Aug; 8(8):609-10. PubMed ID: 19644471
    [No Abstract]   [Full Text] [Related]  

  • 16. GSK moves on Sirtris.
    Sipp D
    Nat Biotechnol; 2008 Jun; 26(6):595. PubMed ID: 18536662
    [No Abstract]   [Full Text] [Related]  

  • 17. An unbalanced portfolio.
    Federsel HJ
    Drug News Perspect; 2009 Jun; 22(5):287-92. PubMed ID: 19609466
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Deal watch: Ablynx and Merck Serono collaborate on next-generation antibody products.
    Nat Rev Drug Discov; 2008 Nov; 7(11):881. PubMed ID: 18974745
    [No Abstract]   [Full Text] [Related]  

  • 19. Strategic groups in the biopharmaceutical industry: implications for performance.
    Erden Z; von Krogh G; Nytorp C; Hultberg M
    Drug Discov Today; 2009 Aug; 14(15-16):726-30. PubMed ID: 19416760
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Brazil: An emerging partner in drug R&D.
    Rodrigues DG
    IDrugs; 2009 Aug; 12(8):497-502. PubMed ID: 19629884
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.